PHARMAZONE
GenericsPHARMAZONE is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.
PHARMAZONE's Key Drugs
PHARMAZONE's core commercial portfolio centers on PRASUGREL, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Thrombotic Cardiovascular Events
Hypertension
Heart Failure
PHARMAZONE's Recent FDA Approvals
PHARMAZONE secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
PHARMAZONE's Therapeutic Areas
PHARMAZONE's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMAZONE's Top Competitors
PHARMAZONE's closest competitors by therapeutic-area and drug-target overlap include LEDERLE, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMAZONE Pipeline Snapshot
Active clinical trials for PHARMAZONE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PRASUGREL leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (4)
Company Info
- First Approval
- 1964-06-29
- Latest
- 2026-09-30
- Applications
- 157